Research Papers:

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

Zachary C. Dobbin, Ashwini A. Katre, Adam D. Steg, Britt K. Erickson, Monjri M. Shah, Ronald D. Alvarez, Michael G. Conner, David Schneider, Dongquan Chen and Charles N. Landen _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:8750-8764. https://doi.org/10.18632/oncotarget.2373

Metrics: PDF 4991 views  |   HTML 4531 views  |   ?  


Zachary C. Dobbin1,2, Ashwini A. Katre1, Adam D. Steg1, Britt K. Erickson1, Monjri M. Shah1, Ronald D. Alvarez1, Michael G. Conner3, David Schneider4, Dongquan Chen5 and Charles N. Landen6

1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham

2 NIH Medical Scientist Training Program, University of Alabama at Birmingham

3 Department of Pathology, University of Alabama at Birmingham

4 Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham

5 Division of Preventative Medicine, Department of Medicine, University of Alabama at Birmingham

6 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Virginia, Charlottesville, VA


Charles N. Landen Jr, email:

Keywords: Ovarian Cancer, Patient-derived xenograft, cancer stem cells, chemoresistance, animal models of cancer

Received: August 08, 2014 Accepted: August 18, 2014 Published: August 19, 2014


A cornerstone of preclinical cancer research has been the use of clonal cell lines. However, this resource has underperformed in its ability to effectively identify novel therapeutics and evaluate the heterogeneity in a patient’s tumor. The patient-derived xenograft (PDX) model retains the heterogeneity of patient tumors, allowing a means to not only examine efficacy of a therapy, but also basic tenets of cancer biology in response to treatment. Herein we describe the development and characterization of an ovarian-PDX model in order to study the development of chemoresistance. We demonstrate that PDX tumors are not simply composed of tumor-initiating cells, but recapitulate the original tumor’s heterogeneity, oncogene expression profiles, and clinical response to chemotherapy. Combined carboplatin/paclitaxel treatment of PDX tumors enriches the cancer stem cell populations, but persistent tumors are not entirely composed of these populations. RNA-Seq analysis of six pair of treated PDX tumors compared to untreated tumors demonstrates a consistently contrasting genetic profile after therapy, suggesting similar, but few, pathways are mediating chemoresistance. Pathways and genes identified by this methodology represent novel approaches to targeting the chemoresistant population in ovarian cancer

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2373